NOVEL APPROACHES FOR ANEMIA IN CARDIORENAL SYNDROME: A RANDOMIZED CONTROLLED TRIAL OF HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR VS SGLT2 INHIBITOR

LAXMI SANKALPA BHAGANAGARAPU; SARUMATHY SUNDARARAJAN

doi:10.22159/ajpcr.2025v18i12.57009

Authors

LAXMI SANKALPA BHAGANAGARAPU Department of Pharmacy Practice, SRM College of Pharmacy, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Chengalpattu, Tamil Nadu, India
SARUMATHY SUNDARARAJAN Department of Pharmacy Practice, SRM College of Pharmacy, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Chengalpattu, Tamil Nadu, India

DOI:

https://doi.org/10.22159/ajpcr.2025v18i12.57009

Keywords:

Anemia, Cardiorenal syndrome, Desidustat, Dapagliflozin, Hematological parameters

Abstract

Objectives: The study was designed to compare and discern the effects of desidustat versus dapagliflozin in managing anemia in addition to the standard treatment in cardiorenal syndrome (CRS).

Methods: Patients were randomly allocated into three groups: Group A (standard heart failure therapy+oral hypoglycemics), Group B (standard therapy+dapagliflozin), and Group C (standard therapy+desidustat). At baseline, 12 weeks, and 24 weeks, the hematology, iron-related parameters were estimated. The Kidney Disease Quality of Life questionnaire (KDQOL-36) was used to evaluate the quality of life of these patients.

Results: After 24 weeks, Group C exhibited significant improvements with a rise in hemoglobin (Hb) (p=0.001), other hematology, and iron parameters. Group B showed a modest but significant increase in Hb (p=0.04) alongside improved glycemic parameters. In contrast, KDQOL scores improved in Group C, specifically for the burden of kidney disease (p=0.03), symptoms (p=0.001), and daily life impact (p=0.001). Group B also showed significant changes in the burden of kidney disease (p=0.04), symptoms (p=0.002), and daily life impact (p=0.001). In Group A, significant changes were observed in the burden of kidney disease (p=0.001) and the impact on daily life (p=0.01).

Conclusion: Desidustat demonstrated greater hematopoietic efficacy compared to dapagliflozin and standard therapy alone, hence emerging as a better treatment choice over conventional treatment in managing anemia in CRS.

Downloads

Download data is not yet available.

References

1. Georgiev K, Hvarchanova N, Georgieva M, Kanazirev B. Potential drug-drug interactions in heart failure patients. Int J Pharm Pharm Sci. 2019;11:37-41. doi: 10.22159/ijpps.2019v11i9.33585

2. Rangaswami J, Bhalla V, Blair JE, Chang TI, Costa S, Lentine KL, et al. Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association. Circulation. 2019;139(16):e840-78. doi: 10.1161/ CIR.0000000000000664, PMID 30852913

3. Cappellini MD, Motta I. Anemia in clinical practice-definition and classification: Does hemoglobin change with aging? Semin Hematol. 2015;52(4):261-9. doi: 10.1053/j.seminhematol.2015.07.006, PMID 26404438

4. Vittalrao AM, Thanusubramanian H, Kumari KM, Shaik AB. Pharmacotherapy of heart failure. Asian J Pharm Clin Res. 2018;11(6):78-87. doi: 10.22159/ajpcr.2018.v11i6.23712

5. McCullough PA. Anemia of cardiorenal syndrome. Kidney Int Suppl (2011). 2021;11(1):35-45. doi: 10.1016/j.kisu.2020.12.001, PMID 33777494

6. Marques Vidas M, Portolés J, Cobo M, Gorriz JL, Nuñez J, Cases A. Anemia management in the cardiorenal patient: A nephrological perspective. J Am Heart Assoc. 2025;14(5):e037363. doi: 10.1161/ JAHA.124.037363, PMID 40028884

7. Alexandrakis MG, Tsirakis G. Anemia in heart failure patients. ISRN Hematol. 2012;2012:246915. doi: 10.5402/2012/246915, PMID 22536520

8. Anand IS, Gupta P. Anemia and iron deficiency in heart failure: Current concepts and emerging therapies. Circulation. 2018;138(1):80-98. doi: 10.1161/CIRCULATIONAHA.118.030099, PMID 29967232

9. Mozos I. Mechanisms linking red blood cell disorders and cardiovascular diseases. BioMed Res Int. 2015;2015:682054. doi: 10.1155/2015/682054, PMID 25710019

10. Leermakers PA, Remels AH, Zonneveld MI, Rouschop KM, Schols AM, Gosker HR. Iron deficiency-induced loss of skeletal muscle mitochondrial proteins and respiratory capacity; The role of mitophagy and secretion of mitochondria-containing vesicles. FASEB J. 2020;34(5):6703-17. doi: 10.1096/fj.201901815R, PMID 32202346

11. Alnuwaysir RI, Hoes MF, Van Veldhuisen DJ, Van Der Meer P, Grote Beverborg NG. Iron deficiency in heart failure: Mechanisms and pathophysiology. J Clin Med. 2021;11(1):125. doi: 10.3390/ jcm11010125, PMID 35011874

12. MacDougall IC. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: Oral or intravenous? Curr Med Res Opin. 2010;26(2):473-82. doi: 10.1185/03007990903512461, PMID 20014980

13. Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, et al. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014;29(11):2075-84. doi: 10.1093/ndt/gfu201, PMID 24891437

14. Milic S, Mikolasevic I, Orlic L, Devcic E, Starcevic-Cizmarevic N, Stimac D, et al. The role of iron and iron overload in chronic liver disease. Med Sci Monit. 2016;22:2144-51. doi: 10.12659/MSM.896494, PMID 27332079

15. Kontoghiorghes GJ. Iron load toxicity in medicine: From molecular and cellular aspects to clinical implications. Int J Mol Sci. 2023;24(16):12928. doi: 10.3390/ijms241612928, PMID 37629109

16. Thavarajah S, Choi MJ. Scopus C, Google Scholar P. The Use of Erythropoiesis-Stimulating Agents in Patients with CKD and Cancer: A Clinical Approach the Effect of Anemia Treatment on Selected Health Related Quality of Life Domains: A Systematic Review 2019. In Practice. Available from: https://www.ajkd.org/article/s0272-6386

17. Seliger SL, Zhang AD, Weir MR, Walker L, Hsu VD, Parsa A, et al. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int. 2011;80(3):288-94. doi: 10.1038/ki.2011.49, PMID 21389972

18. Garimella PS, Katz R, Patel KV, Kritchevsky SB, Parikh CR, Ix JH, et al. Association of serum erythropoietin with cardiovascular events, kidney function decline, and mortality: The health aging and body composition study. Circ Heart Fail. 2016;9(1):e002124. doi: 10.1161/ CIRCHEARTFAILURE.115.002124, PMID 26721912

19. Banerjee S, Panas R. Diabetes and cardiorenal syndrome: Understanding the “triple threat.” Hellenic J Cardiol. 2017;58(5):342-7. doi: 10.1016/j. hjc.2017.01.003, PMID 28089648

20. Yosmar R, Shepany E, Fitria N. A comprehensive analysis of antidiabetic drug interactions in geriatric non-insulin dependent diabetes mellitus patients. Int J Appl Pharm. 2024;16 Suppl 1:62-5. doi: 10.22159/ ijap.2024.v16s1.12

21. Schechter M, Melzer Cohen C, Yanuv I, Rozenberg A, Chodick G, Bodegård J, et al. Epidemiology of the diabetes-cardio-renal spectrum: A cross-sectional report of 1.4 million adults. Cardiovasc Diabetol. 2022;21(1):104. doi: 10.1186/s12933-022-01521-9, PMID 35689214

22. Wright EM. SGLT2 inhibitors: Physiology and pharmacology. Kidney360. 2021;2(12):2027-37. doi: 10.34067/kid.0002772021, PMID 35419546

23. Docherty KF, Curtain JP, Anand IS, Bengtsson O, Inzucchi SE, Køber L, et al. Effect of dapagliflozin on anaemia in DAPA-HF. Eur J Heart Fail. 2021;23(4):617-28. doi: 10.1002/ejhf.2132, PMID 33615642

24. Heerspink HJ, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-46. doi: 10.1056/nejmoa2024816, PMID 32970396

25. Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci. 2022;23(7):3651. doi: 10.3390/ijms23073651, PMID 35409011

26. Ghanim H, Abuaysheh S, Hejna J, Green K, Batra M, Makdissi A, et al. Dapagliflozin suppresses hepcidin and increases erythropoiesis. J Clin Endocrinol Metab. 2020;105(4):dgaa057. doi: 10.1210/clinem/ dgaa057, PMID 32044999

27. Gang S, Khetan P, Varade D, Chinta VR, Mavani S, Gupta U, et al. Desidustat in anemia due to dialysis-dependent chronic kidney disease: A Phase 3 study (DREAM-D). Am J Nephrol. 2022;53(5):343-51. doi: 10.1159/000523949, PMID 35462369

28. Agrawal D, Varade D, Shah H, Nazar A, Krishnan J, Shukla V, et al. Desidustat in anemia due to non-dialysis-dependent chronic kidney disease: A phase 3 study (DREAM-ND). Am J Nephrol. 2022;53(5):352-60. doi: 10.1159/000523961, PMID 35462372

29. Kumar A, Sharma E, Marley A, Samaan MA, Brookes MJ. Iron deficiency anaemia: Pathophysiology, assessment, practical management. BMJ Open Gastroenterol. 2022;9(1):e000759. doi: 10.1136/bmjgast-2021-000759, PMID 34996762

30. Docherty KF, Welsh P, Verma S, De Boer RA, O’Meara E, Bengtsson O, et al. Iron deficiency in heart failure and effect of dapagliflozin: Findings from DAPA-HF. Circulation. 2022;146(13):980-94. doi: 10.1161/ CIRCULATIONAHA.122.060511, PMID 35971840

31. Henry RR, Strange P, Zhou R, Pettus J, Shi L, Zhuplatov SB, et al. Effects of dapagliflozin on 24-hour glycemic control in patients with type 2 diabetes: A randomized controlled trial. Diabetes Technol Ther. 2018;20(11):715-24. doi: 10.1089/dia.2018.0052, PMID 30222367

32. Hoshino J, Muenz D, Zee J, Sukul N, Speyer E, Guedes M, et al. Associations of hemoglobin levels with health-related quality of life, physical activity, and clinical outcomes in persons with Stage 3-5 nondialysis CKD. J Ren Nutr. 2020;30(5):404-14. doi: 10.1053/j. jrn.2019.11.003, PMID 31980326

33. Zimbudzi E, Lo C, Ranasinha S, Gallagher M, Fulcher G, Kerr PG, et al. Predictors of health-related quality of life in patients with co-morbid diabetes and chronic kidney disease. PLOS One. 2016;11(12):e0168491. doi: 10.1371/journal.pone.0168491, PMID 27992595

34. Yang J, Shen SH, Wang WL, Wang YY, Liu JJ. Roxadustat improves psychological stress and life quality of patients with uremia during hemodialysis. Int J Pharmacol. 2022;18(3):527-33. doi: 10.3923/ ijp.2022.527.533

35. Sonaglioni A, Lonati C, Tescaro L, Nicolosi GL, Proietti M, Lombardo M, et al. Prevalence and clinical outcome of main echocardiographic and hemodynamic heart failure phenotypes in a population of hospitalized patients 70 years old and older. Aging Clin Exp Res. 2022;34(5):1081-94. doi: 10.1007/s40520-021-02025-4, PMID 34988931